分子诊断公司BillionToOne（股票代码：BLLN）今日在纳斯达克证券交易所首次亮相，股价表现亮眼，盘中大涨66.67%，引发市场广泛关注。
据悉，BillionToOne的IPO发行价为每股60美元，而开盘价高达100美元，较发行价溢价66.7%。公司此次共发行456万股股票，成功募集资金2.731亿美元。值得注意的是，BillionToOne最初计划发行385万股，每股价格区间为49美元至55美元，但最终定价明显高于预期区间。
总部位于加利福尼亚州门洛帕克市的BillionToOne主要开发分子诊断测试，包括针对各种疾病的无创产前筛查和液体活检。公司近期财务表现强劲，截至6月30日的六个月内，收入同比增长82%至1.255亿美元，净亏损缩小至420万美元。此次成功上市不仅为BillionToOne带来了可观的融资，也反映了投资者对其业务前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.